Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...

Up to a few decades ago a considerable proportion of patients with hemophilia died prematurely because of hemophilia. Tragically, many deaths were the result of childhood injury or surgery. Over the ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by low levels of the blood protein called factor 9. Factor 9 is a specialized protein necessary for blood ...

Steven W. Pipe, MD, shares insights on optimizing hemophilia treatment schedules and minimizing hoarding of factor VIII prophylaxis or emicizumab for improved patient adherence. This is a video ...

Approval of valoctocogene roxaparvovec for adults with severe hemophilia A was based on data from the global phase III GENEr8-1 study, in which the therapy reduced the average annualized bleeding rate ...

ATLANTA, Georgia — It's a problem many clinicians would love to have: a whole variety of new or emerging therapeutic options to use in the care of their patients. In a session titled "Hemophilia ...

Hemgenix's list price will be $3.5 million, the highest cost yet for a single-dose drug. Reading time 3 minutes A novel medication for hemophilia B has just been approved by the Food and Drug ...

Understand key factors influencing hemophilia A treatment decisions and explore the impact of prophylactic vs on-demand therapy on efficacy, safety, and patient outcomes, including joint health, ...

Results showed marstacimab was superior to on-demand factor replacement and was noninferior to prophylactic factor-based therapy. The Food and Drug Administration (FDA) has approved Hympavzi ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for its anti-tissue ...

Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets, citing weak demand. "Pfizer has made the ...